Phase I/II clinical trial of stereotactic body radiotherapy in patients with cervical cancer who are unsuitable for intracavitary brachytherapy

Phase I/II clinical trial of image-guided 3 dimensional beam-convergent and extremely hypofractionated radiotherapy for patients with cervical cancer unsuitable for intracavitary brachytherapy - Phase I/II clinical trial of image-guided 3 dimensional beam-convergent and extremely hypofractionated RT for patients with cervical cancer unsuitable for ICBT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036845

Enrollment

Registered

2019-07-01

Start date

2019-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine cervical cancer

Interventions

Whole pelvic irradiation using IMRT (45 Gy/25 fr.), followed by extremely hypofractionated radiotherapy (21 Gy/3 fr.)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. pathological diagnosis of primary cervical cancer 2. FIGO stage; Ib1-IIIB 3. N stage 0-1, M status 0-1 (PAN metastases only) 4. Unsuitable for intracavitary brachytherapy 5. ECOG PS; 0-2 6. No previous radiotherapy in the pelvic organs

Exclusion criteria

Exclusion criteria: 1. Serious medical or psychological problems 2. Other active cancer within 3 years 3. Be pregnant or just after giving birth

Design outcomes

Primary

Measure	Time frame
Progression-free survival at 2 years	—

Countries

Japan

Contacts

Public ContactKei Ito

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Dept. of Radiation Oncology

keiito@cick.jp03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026